AbCellera Biologics Analyst Ratings
AbCellera Biologics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/13/2023 | 395.05% | Piper Sandler | → $20 | Assumes | → Overweight |
| 08/31/2023 | 197.03% | Benchmark | $20 → $12 | Maintains | Buy |
| 08/04/2023 | 494.06% | Goldman Sachs | $27 → $24 | Maintains | Buy |
| 05/05/2023 | 593.07% | Credit Suisse | $34 → $28 | Maintains | Outperform |
| 02/28/2023 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 02/22/2023 | 692.08% | BMO Capital | $40 → $32 | Maintains | Outperform |
| 02/22/2023 | 741.58% | Credit Suisse | → $34 | Reiterates | → Outperform |
| 01/06/2023 | 345.54% | SVB Leerink | $20 → $18 | Maintains | Outperform |
| 12/15/2022 | 642.57% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 11/16/2022 | 617.82% | Truist Securities | → $29 | Initiates Coverage On | → Buy |
| 11/09/2022 | 395.05% | SVB Leerink | $13 → $20 | Maintains | Outperform |
| 08/10/2022 | 741.58% | Credit Suisse | $40 → $34 | Maintains | Outperform |
| 07/26/2022 | 444.55% | Piper Sandler | $21 → $22 | Maintains | Overweight |
| 05/11/2022 | 419.8% | Piper Sandler | $28 → $21 | Maintains | Overweight |
| 05/11/2022 | 246.53% | SVB Leerink | $20 → $14 | Maintains | Outperform |
| 02/25/2022 | 890.1% | Credit Suisse | $39 → $40 | Maintains | Outperform |
| 02/25/2022 | 395.05% | SVB Leerink | $25 → $20 | Maintains | Outperform |
| 12/21/2021 | 568.32% | Benchmark | → $27 | Initiates Coverage On | → Buy |
| 11/19/2021 | 716.83% | Piper Sandler | → $33 | Initiates Coverage On | → Overweight |
| 08/13/2021 | 1112.87% | Credit Suisse | $51 → $49 | Maintains | Outperform |
| 05/14/2021 | 1162.38% | Credit Suisse | $53 → $51 | Maintains | Outperform |
| 03/30/2021 | 1261.39% | Stifel | $59 → $55 | Maintains | Buy |
| 02/08/2021 | 1187.13% | SVB Leerink | $45 → $52 | Maintains | Outperform |
| 01/05/2021 | 1211.88% | Berenberg | → $53 | Initiates Coverage On | → Buy |
| 01/05/2021 | 1013.86% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 01/05/2021 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/05/2021 | 1360.4% | Stifel | → $59 | Initiates Coverage On | → Buy |
| 01/05/2021 | 1088.12% | BMO Capital | → $48 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年10月13日 | 395.05% | 派珀·桑德勒 | →$20 | 假設 | →超重 |
| 2023年08月31日 | 197.03% | 基準 | $20→$12 | 維護 | 買 |
| 08/04/2023 | 494.06% | 高盛 | $27→$24 | 維護 | 買 |
| 05/05/2023 | 593.07% | 瑞士信貸 | $34→$28 | 維護 | 跑贏大盤 |
| 02/28/2023 | - | 考恩公司 | 開始承保 | →跑贏大盤 | |
| 02/22/2023 | 692.08% | 蒙特利爾銀行資本 | $40→$32 | 維護 | 跑贏大盤 |
| 02/22/2023 | 741.58% | 瑞士信貸 | →$34 | 重申 | →跑贏大盤 |
| 01/06/2023 | 345.54% | SVB Leerink | $20→$18 | 維護 | 跑贏大盤 |
| 2022年12月15日 | 642.57% | 高盛 | →$30 | 開始承保 | →購買 |
| 2022年11月16日 | 617.82% | Truist證券 | →$29 | 開始承保 | →購買 |
| 11/09/2022 | 395.05% | SVB Leerink | $13→$20 | 維護 | 跑贏大盤 |
| 2022年08月10日 | 741.58% | 瑞士信貸 | $40→$34 | 維護 | 跑贏大盤 |
| 07/26/2022 | 444.55% | 派珀·桑德勒 | $21→$22 | 維護 | 超重 |
| 2022年05月11日 | 419.8% | 派珀·桑德勒 | $28→$21 | 維護 | 超重 |
| 2022年05月11日 | 246.53% | SVB Leerink | $20→$14 | 維護 | 跑贏大盤 |
| 02/25/2022 | 890.1% | 瑞士信貸 | $39→$40 | 維護 | 跑贏大盤 |
| 02/25/2022 | 395.05% | SVB Leerink | $25→$20 | 維護 | 跑贏大盤 |
| 2021/12/21 | 568.32% | 基準 | →$27 | 開始承保 | →購買 |
| 2021年11月19日 | 716.83% | 派珀·桑德勒 | →$33 | 開始承保 | →超重 |
| 2021/08/13 | 1112.87% | 瑞士信貸 | $51→$49 | 維護 | 跑贏大盤 |
| 2021/05/14 | 1162.38% | 瑞士信貸 | $53→$51 | 維護 | 跑贏大盤 |
| 03/30/2021 | 1261.39% | Stifel | $59→$55 | 維護 | 買 |
| 02/08/2021 | 1187.13% | SVB Leerink | $45→$52 | 維護 | 跑贏大盤 |
| 01/05/2021 | 1211.88% | 貝倫伯格 | →$53 | 開始承保 | →購買 |
| 01/05/2021 | 1013.86% | SVB Leerink | →$45 | 開始承保 | →跑贏大盤 |
| 01/05/2021 | - | 瑞士信貸 | 開始承保 | →跑贏大盤 | |
| 01/05/2021 | 1360.4% | Stifel | →$59 | 開始承保 | →購買 |
| 01/05/2021 | 1088.12% | 蒙特利爾銀行資本 | →$48 | 開始承保 | →跑贏大盤 |
What is the target price for AbCellera Biologics (ABCL)?
AbCellera Biologics(ABCL)的目標價是多少？
The latest price target for AbCellera Biologics (NASDAQ: ABCL) was reported by Piper Sandler on October 13, 2023. The analyst firm set a price target for $20.00 expecting ABCL to rise to within 12 months (a possible 395.05% upside). 11 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年10月13日報道了AbCellera Biologics(納斯達克：ABCL)的最新目標價。這家分析公司將目標價定為20美元，預計ABCL將在12個月內上漲至20美元(可能上漲395.05%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for AbCellera Biologics (ABCL)?
AbCellera Biologics(ABCL)的最新分析師評級是多少？
The latest analyst rating for AbCellera Biologics (NASDAQ: ABCL) was provided by Piper Sandler, and AbCellera Biologics their overweight rating.
納斯達克(Sequoia Capital：ABCL)的最新分析師評級由Piper Sandler提供，AbCellera Biologics的增持評級。
When is the next analyst rating going to be posted or updated for AbCellera Biologics (ABCL)?
AbCellera Biologics(ABCL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbCellera Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbCellera Biologics was filed on October 13, 2023 so you should expect the next rating to be made available sometime around October 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與AbCellera Biologics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。AbCellera Biologics的最後一次評級是在2023年10月13日提交的，所以你應該預計下一次評級將在2024年10月13日左右的某個時候提供。
Is the Analyst Rating AbCellera Biologics (ABCL) correct?
分析師評級AbCellera Biologics(ABCL)正確嗎？
While ratings are subjective and will change, the latest AbCellera Biologics (ABCL) rating was a with a price target of $0.00 to $20.00. The current price AbCellera Biologics (ABCL) is trading at is $4.04, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但AbCellera Biologics(ABCL)的最新評級為A，目標價在0.00美元至20.00美元之間。AbCellera Biologics(ABCL)目前的交易價格為4.04美元，在分析師的預測範圍內。